Literature DB >> 17855036

Sonographic findings of the median nerve and prevalence of carpal tunnel syndrome in patients with Parkinson's disease.

Aylin Yucel, Ozge Yilmaz, Secil Babaoglu, Murat Acar, Bumin Degirmenci.   

Abstract

PURPOSE: Parkinson's disease (PD) is a chronic progressive disorder which is characterized by rest tremor, akinesia or bradykinesia and rigidity. Carpal tunnel syndrome (CTS) is caused by compression of median nerve and can occur as a result of repetitive trauma. The aim of this study was to estimate the prevalence of CTS in PD and evaluate the median nerve sonographically.
MATERIALS AND METHODS: Fifty-three wrist of 29 patients with PD were included in the study according to Hoehn and Yahr (H&Y) clinical stage and divided into two groups. The first group consisted of 29 wrists of patients with mild PD (H&Y stage I-II). The second group consisted of 24 wrists of patients with severe PD (H&Y stage III-IV). Thirty-six wrists of 20 age-matched patients were used as control group. Both of the patients with PD and control group underwent sonography and electromyography (EMG). Axial sonograms of the median nerve were obtained at the level of distal radioulnar joint (level 1) and at the level of pisiform bone in the carpal tunnel (level 2). At each level, the cross-sectional area of the median nerve and flattening ratio were calculated.
RESULTS: There was no significant difference for all parameters, except one parameter, between the patients with PD and control group, and also among mild and severe groups of PD and control group (p>0.05). Interestingly, amplitude of median nerve in the second finger was significantly lower in PD patients than control group within normal limits (p=0.010). Of all wrists of PD patients, 13 (24.4%) have been diagnosed as CTS and 7 (19.4%) control wrists had CTS. Median nerve cross-sectional area of CTS patients were more than 10mm(2) in 6 (46%) wrists of PD patients but in only 1 (14%) control wrist at each level. Although it was not statistically significant, there was higher cross-sectional area at each level in patients with severe PD (level 1: 10.43+/-2.30 mm(2), level 2: 10.35+/-3.19 mm(2)) than patients with mild PD (level 1: 9.93+/-2.61 mm(2), level 2: 9.51+/-2.83 mm(2)) and control group (level 1: 9.69+/-3.19 mm(2), level 2: 9.07+/-3.61 mm(2)).
CONCLUSION: PD may pose a risk for the development of CTS due to the repetitive movement of tremor. Although sonography is not an ideal method of diagnosis for CTS, it may take our attention for indicating CTS in patients with PD especially in severe ones.

Entities:  

Mesh:

Year:  2007        PMID: 17855036     DOI: 10.1016/j.ejrad.2007.08.001

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  High incidence of carpal tunnel syndrome after deep brain stimulation in Parkinson's disease.

Authors:  Marine Loizon; Chloé Laurencin; Christophe Vial; Teodor Danaila; Stéphane Thobois
Journal:  J Neurol       Date:  2016-09-13       Impact factor: 4.849

2.  Carpal Tunnel Syndrome in Patients with Tremor Dominant Parkinson's Disease.

Authors:  Sang Won Han; Kyeong Yeol Cheon; Jeong Yeon Kim; Jong Sam Baik
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

3.  Median and Ulnar Neuropathy Assessment in Parkinson's Disease regarding Symptom Severity and Asymmetry.

Authors:  Nilgul Yardimci; Ozlem Cemeroglu; Eda Ozturk; Gülsüm Gürlü; Esra Şahin; Saliha Bozkurt; Tugba Cengiz; Gulderen Karali; Hasim Cakirbay; Atilla İlhan
Journal:  Parkinsons Dis       Date:  2016-10-24

4.  Diagnostic potential of ultrasound in carpal tunnel syndrome with different etiologies: correlation of sonographic median nerve measures with electrodiagnostic severity.

Authors:  Basant Elnady; Elsayed M Rageh; Tohamy Ekhouly; Sabry M Fathy; Mohamed Alshaar; El Saeed Fouda; Mohammed Attar; Ahmed M Abdelaal; Ahmed El Tantawi; Mohammed M Algethami; David Bong
Journal:  BMC Musculoskelet Disord       Date:  2019-12-29       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.